Retina

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

Optical coherence tomography will be in all eye care services by October 2025

Program director and co-founder Bonnie An Henderson, MD, sits down with Ophthalmology Times to talk about how the annual conference is a unique blend of cutting-edge science, professional growth, and community. The 2025 conference will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

Options empower patients and providers to decrease treatment burden

Arun Upadhyay, PhD, discusses new study findings from trials of OCU400 (Ocugen)

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need for improved awareness, cost-effectiveness, and integration to increase diabetic retinopathy screening rates.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

New analysis brings disease progression and therapeutics into focus

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that promotes blood vessel growth. Combining anti-VEGF with an experimental drug targeting HIF-1 could enhance vision outcomes and prevent vision loss.

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s non-inferiority objectives, treatment schedule, patient outcomes like reduced treatment burden, and anatomical stability. Patient interest is high, particularly among those wanting fewer injections, though recruiting treatment-naive patients may be challenging. If results are favorable, potential FDA approval could occur within 3 to 4 years.

This year’s Barcelona meeting brought together award-winning research data and leaders in the retina field

To educate the public—including parents, caregivers, and allied health professionals—Prevent Blindness is offering free educational resources, including fact sheets, social media graphics, web pages, and educational videos in both English and Spanish.

Caffeine has been shown to temporarily increase intraocular pressure and reduce blood flow in critical ocular regions

Observations show distinct variations between the changes in optic nerve head (ONH) and the macula.

200 mg of caffeine elevated the blood pressure after 2 hours but did not impact the retinal VD.

AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions

Vaidehi S. Dedania, MD, from the New York University (NYU) Langone Health and the Grossman School of Medicine, spoke with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. She insights from the session, "Preventing and managing complications following vitreoretinal surgery."

Vikas Chopra, MD, from the Doheny Eye Institute of UCLA, caught up with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. He shared how technology has advanced ophthalmic surgery over the years and how hands on sessions at the meeting allow surgeons to train for rare complications that can arise during routine surgeries.

In this final episode, DMEI’s residents share their future plans for expanding the device capabilities and offer practical advice to other up-and-coming creators in eye care technology.

Researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.

Julie Schallhorn, MD, MS, also is an associate professor of ophthalmology at the University of California San Francisco, has drawn upon her bioengineering background to develop a device to simplify eye drop administration.